Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

EB Cunningham; B Hajarizadeh; O Dalgard; J Amin; M Hellard; GR Foster; P Bruggmann; B Conway; M Backmund; G Robaeys; T Swan; PS Marks; S Quiene; TL Applegate; M Weltman; D Shaw; A Dunlop; J Bruneau; H Midgard; S Bourgeois; MC Thurnheer; GJ Dore; J Grebely; I Shaw; S Siriragavan; T Horschik; S Sharma; A Eevers; J Andreassen; I Melkeraaen; N Widder; K Lesneuck; B Kotsoros; S Hazelwood; R Holland; D Axten; S Von Bibra; J Powis; K Mason; S Ryder; K Jack; C Scheidegger; C Huber; C Ferguson; C Staehelin; M Lacalamita; V Fragomeli; A Sevehon

Journal article

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

EB Cunningham, B Hajarizadeh, O Dalgard, J Amin, M Hellard, GR Foster, P Bruggmann, B Conway, M Backmund, G Robaeys, T Swan, PS Marks, S Quiene, TL Applegate, M Weltman, D Shaw, A Dunlop, J Bruneau, H Midgard, S Bourgeois Show all

BMC Infectious Diseases | BIOMED CENTRAL LTD | Published : 2017

DOI: 10.1186/s12879-017-2517-3

Download PDF

Abstract

Background: The aims of this analysis were to investigate treatment completion and adherence among people with ongoing injecting drug use or receiving opioid substitution therapy (OST) in a study of response-guided therapy for chronic HCV genotypes 2/3 infection. Methods: ACTIVATE was a multicenter clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4). Outcomes included treatment completion, PEG-IFN adherence, ribavirin adherence, and sustained virological response (SVR, undetectable H..

View full abstract

University of Melbourne Researchers

Margaret Hellard Author

Grants

Funding Acknowledgements

Supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. BH is supported by a National Health and Medical Research Council Early Career Fellowship. MH is supported by a National Health and Medical Research Council Principal Research Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships.